Hussman Strategic Advisors Inc. Makes New Investment in Integra LifeSciences Holdings Corporation $IART

Hussman Strategic Advisors Inc. purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) during the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 168,000 shares of the life sciences company’s stock, valued at approximately $2,407,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IART. Systematic Financial Management LP boosted its holdings in Integra LifeSciences by 12.8% in the 2nd quarter. Systematic Financial Management LP now owns 1,056,920 shares of the life sciences company’s stock valued at $12,968,000 after purchasing an additional 120,086 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new position in Integra LifeSciences in the second quarter valued at approximately $632,000. Edgestream Partners L.P. purchased a new position in Integra LifeSciences in the second quarter worth approximately $739,000. Sapience Investments LLC increased its stake in Integra LifeSciences by 53.3% during the second quarter. Sapience Investments LLC now owns 218,992 shares of the life sciences company’s stock worth $2,687,000 after acquiring an additional 76,170 shares during the last quarter. Finally, Access Investment Management LLC purchased a new stake in Integra LifeSciences in the second quarter valued at $5,348,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently weighed in on IART. Citigroup lowered their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a report on Friday, October 31st. Truist Financial reaffirmed a “hold” rating and set a $13.00 target price (down previously from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. increased their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, Integra LifeSciences has a consensus rating of “Reduce” and a consensus target price of $15.00.

Insider Transactions at Integra LifeSciences

In other Integra LifeSciences news, Director Jeffrey A. Graves bought 9,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 5th. The shares were purchased at an average price of $11.35 per share, with a total value of $102,150.00. Following the completion of the acquisition, the director directly owned 41,086 shares of the company’s stock, valued at $466,326.10. This represents a 28.05% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 3.54% of the stock is owned by corporate insiders.

Integra LifeSciences Price Performance

Shares of IART opened at $11.13 on Wednesday. The company has a market cap of $866.94 million, a P/E ratio of -1.72 and a beta of 1.02. Integra LifeSciences Holdings Corporation has a fifty-two week low of $10.87 and a fifty-two week high of $27.13. The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73. The firm’s 50 day moving average price is $12.73 and its 200 day moving average price is $13.39.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $0.54 EPS for the quarter, topping the consensus estimate of $0.43 by $0.11. The business had revenue of $402.06 million during the quarter, compared to the consensus estimate of $414.31 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The company’s quarterly revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.41 earnings per share. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. On average, research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.